Home / Health / Bladder Cancer Survival Boosted by New Treatment
Bladder Cancer Survival Boosted by New Treatment
15 Feb
Summary
- Durvalumab shows a 32% reduction in disease progression risk.
- Around 630 patients annually may be eligible for the new therapy.
- NICE approval marks a crucial step for innovative cancer treatments.
Patients diagnosed with an aggressive form of bladder cancer may experience an improved outlook due to the new drug durvalumab. Clinical trials have demonstrated that this immune-boosting medication can effectively halt the progression of muscle-invasive bladder cancer (MIBC) and reduce the need for hospital admissions.
Recently, the NHS spending watchdog, NICE, approved durvalumab for rollout across the NHS. A significant trial involving over 1,000 patients revealed a 32 percent decrease in the risk of disease progression when compared to standard care treatments.
Muscle-invasive bladder cancer represents an advanced stage of the disease. Despite existing treatments, nearly half of patients face recurrence or progression within five years. The new regimen involves administering durvalumab alongside chemotherapy before and after the complete removal of the bladder.
Approximately 630 patients annually are anticipated to be eligible for this therapy. Experts have lauded the NICE approval, emphasizing its critical importance for patients facing life-changing diagnoses. Doctors involved in the trials have expressed optimism, noting that this new standard of care could lead to more patients being cured of this challenging cancer.
